(Q33988126)

30 July 2017

1 reference

title

Adverse effects and other safety aspects of the hepatitis C antivirals (English)

1 reference

30 July 2017

1 reference

Chutaputti A

1

1 reference

PubMed ID

10921400

30 July 2017

language of work or name

1 reference

1 May 2000

1 reference

Journal of Gastroenterology and Hepatology

30 July 2017

1 reference

30 July 2017

15 Suppl

1 reference

30 July 2017

E156-63

1 reference

Side effects of alpha interferon in chronic hepatitis C.

30 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Side effects of alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

21 January 2018

Therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Side effects of high-dose interferon therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Interferon-related cortical blindness

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Seizures during alpha interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Seizures associated with low-dose alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Hazards of interferon therapy for HBV-seronegative chronic hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Longitudinal Study of Antibodies against Thyroid in Patients Undergoing Interferon-&alpha; Therapy for HCV Chronic Hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Systemic lupus erythematosus in a child receiving long-term interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Exacerbation of primary biliary cirrhosis during interferon-alpha 2b therapy for chronic active hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Fibrillary glomerulonephritis associated with hepatitis C viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Sudden hearing loss associated with interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Adding ribavirin to interferon alpha-2b for chronic hepatitis C infection increased virological response and nausea

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02114.X

10.1046/J.1440-1746.2000.02114.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10921400